Soleno Therapeutics ( (SLNO) ) has released its Q3 earnings. Here is a breakdown of the information Soleno Therapeutics presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases, with its primary product being VYKAT XR, a treatment for hyperphagia in Prader-Willi syndrome (PWS) patients.
In the third quarter of 2025, Soleno Therapeutics reported significant financial growth, achieving a net income of $26 million, driven by the successful U.S. launch of VYKAT XR, which generated $66 million in revenue. The company also raised $230 million through a common stock offering, strengthening its financial position.
Key financial highlights include a substantial increase in product revenue from the previous quarter, a reduction in research and development expenses compared to the previous year, and increased selling, general, and administrative expenses due to the commercial launch of VYKAT XR. The company also appointed Mark W. Hahn to its Board of Directors, enhancing its strategic leadership.
Looking ahead, Soleno Therapeutics is optimistic about the continued growth and accessibility of VYKAT XR as a foundational therapy for PWS patients, aiming to expand its reach and impact within this niche market.